keyword
MENU ▼
Read by QxMD icon Read
search

formulary

keyword
https://www.readbyqxmd.com/read/29328042/dynamics-of-changes-in-indices-of-endogenous-intoxication-in-patients-with-acute-small-intestinal-obstruction-in-case-of-reamberin-use-in-the-comprehensive-treatment
#1
V Skrypko, A Kovalenko, E Talikova
The objective of this research was to study changes in parameters, characterizing endogenous intoxication in patients with acute small bowel obstruction with Reamberin included into therapy scheme. Full physical examination and surgical treatment of 202 patients with acute small bowel obstruction were conducted. The control group included 30 healthy individuals. Dynamics of such clinical biochemical parameters as medium mass molecules (MMM), malondialdehyde (MDA), diene conjugates (DC) in blood serum were analyzed in preoperative period and on the 1st, 5th and 14th day of postoperative period...
December 2017: Georgian Medical News
https://www.readbyqxmd.com/read/29326146/prior-authorization-requirements-for-proprotein-convertase-subtilisin-kexin-type-9-inhibitors-across-us-private-and-public-payers
#2
Jalpa A Doshi, Justin T Puckett, Michael S Parmacek, Daniel J Rader
BACKGROUND: Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9is) are an innovative treatment option for patients with familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease who require further lowering of low-density lipoprotein cholesterol. However, the high costs of these agents have spurred payers to implement utilization management policies to ensure appropriate use. We examined prior authorization (PA) requirements for PCSK9is across private and public US payers...
January 2018: Circulation. Cardiovascular Quality and Outcomes
https://www.readbyqxmd.com/read/29316960/pregabalin-versus-gabapentin-in-the-treatment-of-sciatica-study-protocol-for-a-randomised-double-blind-cross-over-trial-pagpros
#3
Kelvin Robertson, Laurence A G Marshman, Maria Hennessy, Linton Harriss, David Plummer
BACKGROUND: There is currently an absence of high-grade evidence regarding the treatment of chronic sciatica (CS). Whilst gabapentin (GBP) and pregabalin (PGB) are both currently used to treat CS, equipoise exists regarding their individual use. In particular, no head-to-head study of GBP and PGB in CS exists. Despite equipoise, most countries' formulary regulatory authorities typically favour one drug for subsidy over the other. This hinders interchange wherever the favoured drug is either ineffective or not tolerated...
January 9, 2018: Trials
https://www.readbyqxmd.com/read/29302790/optimizing-the-dosing-of-intravenous-theophylline-in-acute-severe-asthma-in-children
#4
Gemma L Saint, Malcolm G Semple, Ian Sinha, Daniel B Hawcutt
Optimizing the management of children presenting with acute severe asthma is of utmost importance to minimize hospital stays, morbidity, and mortality. Intravenous medications, including theophyllines, are used as second-line treatments for children experiencing a life-threatening exacerbation. For intravenous theophylline (aminophylline), guidelines and formularies recommend a target therapeutic range between 10 and 20 mg/l, with the commonest regimen being a loading dose of 5 mg/kg followed by an infusion calculated by age and weight...
January 5, 2018: Paediatric Drugs
https://www.readbyqxmd.com/read/29290169/evaluating-oncology-value-based-frameworks-in-the-u-s-marketplace-and-challenges-in-real-world-application-a-multiple-myeloma-test-case
#5
Laurence M Djatche, Joseph A Goble, Grace Chun, Stefan Varga
BACKGROUND: With the continuous rise in costs for oncology drugs, the American Society of Clinical Oncology (ASCO), the Institute for Clinical and Economic Review (ICER), the Memorial Sloan Kettering Cancer Center's Drug Abacus (DrugAbacus), and the National Comprehensive Cancer Network (NCCN) have developed value-based frameworks (VBFs) to assist stakeholders in formulary and treatment decision-making processes. Since emerging VBFs have the potential to affect available treatment options for patients, it is important to understand the differences associated with these VBFs within various therapeutic areas...
January 2018: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/29276301/impact-of-inpatient-automatic-therapeutic-substitutions-on-postdischarge-medication-prescribing
#6
Pooja J Shah, Jennifer L Cruz, Ashley L Pappas, Kayla M Waldron, Scott W Savage
Background: Automatic therapeutic substitution (ATS) is the act of therapeutic interchange, in which patients are transitioned from a nonformulary preadmission medication to an equivalent formulary medication upon admission. ATS protocols are able to provide several benefits; however, if medications are unreconciled at the time of discharge, then use may lead to duplication or omission resulting in adverse outcomes. The objective was to assess the impact of preidentified ATS protocol use during admission on duplication and omission postdischarge...
October 2017: Hospital Pharmacy
https://www.readbyqxmd.com/read/29276296/formulary-drug-review-ocrelizumab
#7
REVIEW
Zaynah K Ali, Danial E Baker
Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are available online to subscribers...
October 2017: Hospital Pharmacy
https://www.readbyqxmd.com/read/29276285/formulary-drug-review-safinamide
#8
REVIEW
Danial E Baker, Anne P Kim
No abstract text is available yet for this article.
September 2017: Hospital Pharmacy
https://www.readbyqxmd.com/read/29276281/successful-implementation-of-an-antimicrobial-stewardship-program-at-an-academic-medical-center
#9
Carolyn M Bondarenka, John A Bosso
Background: Focus on antimicrobial use and infection prevention from accrediting or regulatory bodies such as the Joint Commission, as well as regulatory agencies such as the Centers for Medicare and Medicaid Services and the Centers for Disease Control, has highlighted the need for continuing development of antimicrobial stewardship programs at healthcare facilities across the country. Methods: Our institution utilized the 2007 Infectious Diseases Society of America and the Society for Healthcare Epidemiology guidelines to direct the evaluation of its antimicrobial use and develop a successful antimicrobial stewardship program...
July 2017: Hospital Pharmacy
https://www.readbyqxmd.com/read/29276274/formulary-drug-review-naldemedine
#10
Danial E Baker
Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are available online to subscribers...
July 2017: Hospital Pharmacy
https://www.readbyqxmd.com/read/29276266/financial-effect-of-a-drug-distribution-model-change-on-a-health-system
#11
Erin M Turingan, Bijan C Mekoba, Samuel M Eberwein, Patricia A Roberts, Ashley L Pappas, Jennifer L Cruz, Lindsey B Amerine
Background: Drug manufacturers change distribution models based on patient safety and product integrity needs. These model changes can limit health-system access to medications, and the financial impact on health systems can be significant. Objective: The primary aim of this study was to determine the health-system financial impact of a manufacturer's change from open to limited distribution for bevacizumab (Avastin), rituximab (Rituxan), and trastuzumab (Herceptin). The secondary aim was to identify opportunities to shift administration to outpatient settings to support formulary change...
June 2017: Hospital Pharmacy
https://www.readbyqxmd.com/read/29276262/formulary-drug-reviews-plecanatide
#12
Danial E Baker
No abstract text is available yet for this article.
June 2017: Hospital Pharmacy
https://www.readbyqxmd.com/read/29276257/production-standard-and-stability-of-compounded-del-nido-cardioplegia-solution
#13
Luis M Pereira, Gregory S Matte, Peter Lutz, Alana Arnold, Al Patterson
Background: The del Nido cardioplegia solution (dNCS) was originally developed for pediatric cardiac surgery, being now also used for adult patients. Hospital pharmacies frequently resort to internal dNCS production which has led to an increase in the need for validated parameters for compounding and storage. Objective: This report defines in-house production standards, as well as the stability of dNCS under optimal storage conditions. Methods: All ingredients were sterile and United States Pharmacopeia (USP)/National Formulary (NF) certified...
December 2017: Hospital Pharmacy
https://www.readbyqxmd.com/read/29276251/formulary-drug-review-edaravone
#14
REVIEW
Zaynah K Ali, Danial E Baker
Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are available online to subscribers...
December 2017: Hospital Pharmacy
https://www.readbyqxmd.com/read/29276237/formulary-drug-review-etelcalcetide
#15
REVIEW
Danial E Baker
Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are available online to subscribers...
November 2017: Hospital Pharmacy
https://www.readbyqxmd.com/read/29274228/prior-authorization-and-canadian-public-utilization-of-direct-acting-oral-anticoagulants
#16
Lulu Gao, Mina Tadrous, Sandra Knowles, Muhammad Mamdani, J Michael Paterson, David Juurlink, Tara Gomes
PURPOSE: Provincial public drug formularies in Canada have different mechanisms for reimbursement of direct-acting oral anticoagulants (DOACs). We investigate how these differences influence DOAC utilization and expenditure across the country. METHODS: We conducted a population-based, cross-sectional study of all out-patient prescriptions for OACs dispensed to public beneficiaries between January 1, 2010, and June 30, 2015. We calculated quarterly rates of OAC use and expenditures stratified by OAC type and province...
November 2017: Healthcare Policy, Politiques de Santé
https://www.readbyqxmd.com/read/29260929/switching-basal-insulins-in-type-2-diabetes-practical-recommendations-for-health-care-providers
#17
Sarah L Anderson, Jennifer M Trujillo, John E Anderson, Robert J Tanenberg
Basal insulin remains the mainstay of treatment of type 2 diabetes when diet changes and exercise in combination with oral drugs and other injectable agents are not sufficient to control hyperglycemia. Insulin therapy should be individualized, and several factors influence the choice of basal insulin; these include pharmacological properties, patient preferences, and lifestyle, as well as health insurance plan formularies. The recent availability of basal insulin formulations with longer durations of action has provided further dosing flexibility; however, patients may need to switch agents throughout therapy for a variety of personal, clinical, or economic reasons...
December 20, 2017: Postgraduate Medicine
https://www.readbyqxmd.com/read/29243331/a-5-year-retrospective-audit-of-prescribing-by-a-critical-care-outreach-team
#18
Mark Wilson
UK prescribing legislation changes made in 2006 and 2012 enabled appropriately qualified nurses to prescribe any licensed medication, and all controlled drugs in schedule 2-5 of the Misuse of Drugs Regulations 2001, for any medical condition within their clinical competence. Critical Care Outreach nurses who are independent nurse prescribers are ideally placed to ensure that acutely ill patients receive treatment without delay. The perceived challenge was how Critical Care Outreach nurses would be able to safely prescribe for a diverse patient group...
December 15, 2017: Nursing in Critical Care
https://www.readbyqxmd.com/read/29239979/monitoring-haloperidol-plasma-concentration-and-associated-adverse-events-in-critically-ill-children-with-delirium-first-results-of-a-clinical-protocol-aimed-to-monitor-efficacy-and-safety
#19
Valerie D Slooff, Desley K van den Dungen, Babette S van Beusekom, Naomi Jessurun, Erwin Ista, Dick Tibboel, Saskia N de Wildt
OBJECTIVES: As delirium in critically ill children is increasingly recognized, more children are treated with the antipsychotic drug haloperidol, while current dosing guidelines are lacking solid evidence and appear to be associated with a high risk of adverse events. We aim to report on the safety and efficacy of a recently implemented clinical dose-titration protocol with active monitoring of adverse events. DESIGN: From July 2014 until June 2015, when a potential delirium was identified by regular delirium scores and confirmed by a child psychiatrist, haloperidol was prescribed according to the Dutch Pediatric Formulary...
December 12, 2017: Pediatric Critical Care Medicine
https://www.readbyqxmd.com/read/29234498/evaluation-of-the-national-return-of-unwanted-medicines-rum-program-in-australia-a-study-protocol
#20
Amanda J Wheeler, Jean Spinks, Emilie Bettington, Fiona Kelly
Background: The National Return of Unwanted Medicines (NatRUM) program in Australia is one of the few nationally coordinated, free-to-consumer schemes to dispose of unwanted medicines globally. This scheme has been in operation since 1996, however, little is known about public awareness of the scheme and its effectiveness in reducing unsafe disposal practices. The study objectives are to undertake a review of (1) the current use of the NatRUM scheme by consumers; and (11) to investigate disposal practices and beliefs of the general population...
2017: Journal of Pharmaceutical Policy and Practice
keyword
keyword
80776
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"